Sarcomatrix to Attend CureDuchenne FUTURES Conference 2024

May 23, 2024 11:45 PM AEST | By EIN Presswire

Google News:

Sarcomatrix to Attend CureDuchenne FUTURES Conference 2024 — Image source: EIN Presswire

Recent News

London-listed Spectris soars 20% on fresh takeover interest from Adven...

Insurance tech firm Slide targets over $2 billion valuation in Nasdaq...

Macro strategist explains why it’s a good time to own Russell 2000

Rio Tinto seeks innovative collaborators at London Tech Week

RENO, NV, UNITED STATES, May 23, 2024 /EINPresswire.com/ -- Sarcomatrix Therapeutics Corp. is thrilled to announce its participation in the upcoming CureDuchenne FUTURES National Conference, taking place from May 23 to May 26, 2024, at the JW Marriott Orlando, Grande Lakes, located at 4040 Central Florida Pkwy, Orlando, FL 32837.

The CureDuchenne FUTURES National Conference is an esteemed annual event dedicated to providing education, fostering connections, and instilling hope within the Duchenne muscular dystrophy community. This year’s conference promises to be transformative, focusing on the latest advancements in Duchenne research and featuring engaging sessions designed to inspire and energize attendees. Alongside insightful presentations and discussions, participants can look forward to a lively social atmosphere, complete with exciting dance activities.

Sarcomatrix is committed to advancing potential treatments for Duchenne muscular dystrophy through rigorous pre-clinical studies, with plans to initiate human trials as soon as feasibly possible. To support these crucial efforts, the company is actively seeking additional funding.

About Sarcomatrix Therapeutics Corp.

At Sarcomatrix, we harness the power of science to develop therapies that significantly enhance and extend lives. We are dedicated to leading the way in quality, safety, and value in the discovery and development of groundbreaking medicines. Our mission is to make a meaningful impact on everyone who depends on us. For the latest updates and information vital to investors, visit our website at www.Sarcomatrix.com. Stay connected with us on X at @Sarcomatrix and @SarcomatrixNews, LinkedIn at /company/sarcomatrix, YouTube, and Facebook at www.facebook.com/sarcomatrix.

Support Sarcomatrix

Sarcomatrix has launched an equity crowdfunding campaign on StartEngine. To learn more, visit www.startengine.com/offering/sarcomatrix. Our initiative aims to accelerate the development of promising drug treatments for muscle diseases. We invite investors to join our team and help drive advancements in medical treatments for conditions affecting millions. Be part of our mission to shape the future of muscle disease therapy and healthcare innovation.

Media Contact:
[email protected]
+1 (775) 525-1795

Investor Contact:
[email protected]

Source: Sarcomatrix^® Therapeutics, Corp.

David Craig
Sarcomatrix Therapeutics Corp.
+1 415-246-3311
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.